-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs – Announces Phase II DOVACC Collaboration Study in Ovarian Cancer with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit, the European Network of Gynaecological Oncological Trial Groups and AstraZeneca
-
Shareholder Notification: Ultimovacs ASA
-
Ultimovacs ASA – Initiates FOCUS Phase II Trial for Universal Cancer Vaccine, UV1, in Head and Neck Cancer Patients Receiving Pembrolizumab
-
Ultimovacs ASA – Announces Positive 5-Year Overall Survival Update from Phase I Combination Trial Evaluating Universal Cancer Vaccine UV1 in Metastatic Melanoma
-
Ultimovacs ASA – Announces the Appointment of Ton Berkien as Chief Business Officer
-
Ultimovacs ASA: Third quarter 2020 result presentation
-
Ultimovacs ASA – Extraordinary General Meeting held on 11 November 2020
-
Ultimovacs ASA: Invitation to third quarter 2020 results webcast presentation
